- $1.73bn
- $1.85bn
- $591.64m
- 71
- 43
- 72
- 66
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 368.62 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.83 | ||
| Price to Tang. Book | 37.84 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.8% | ||
| Return on Equity | -9.07% | ||
| Operating Margin | -18.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 408.83 | 444.45 | 484.33 | 509.73 | 591.64 | 654.56 | 718.48 | 16.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +63.92 | -89.99 | +500.58 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Directors
- Lynn Tetrault NEC (58)
- Mark Mallon CEO (58)
- William Bonello CFO (56)
- George Cardoza CEX (59)
- Clive Morris CEX
- Gina Wallar CEX (46)
- Cynthia Dieter CAO (46)
- Marcus Silva CMO (45)
- Stephanie Bywater CCO (50)
- Kathryn McKenzie CRO (36)
- Denise Pedulla GCN (60)
- Douglas Brown OTH (51)
- Jennifer Balliet OTH (43)
- David Daly DRC
- Bruce Crowther IND (69)
- Alison Hannah IND (59)
- Stephen Kanovsky IND (58)
- Michael Kelly IND (64)
- Rachel Stahler IND (45)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 29th, 1998
- Public Since
- December 10th, 2012
- No. of Shareholders
- 645
- No. of Employees
- 2,100
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 127,665,638
- Address
- 9490 Neogenomics Way, FORT MYERS, 33912
- Web
- https://neogenomics.com/
- Phone
- +1 2397680600
- Contact
- Jeffrey Sherman
- Auditors
- Deloitte & Touche LLP
Latest News for NEO
Upcoming Events for NEO
Q1 2024 Neogenomics Inc Earnings Call
Q1 2024 Neogenomics Inc Earnings Release
Neogenomics Inc Annual Shareholders Meeting
Neogenomics Inc Annual Shareholders Meeting
Q2 2024 Neogenomics Inc Earnings Release
Similar to NEO
ADVANCED BIOMED
NASDAQ Capital Market
Aesthetic Medical International Holdings
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
American Oncology Network
NASDAQ Capital Market
Assure Holdings
NASDAQ Capital Market
FAQ
As of Today at 19:15 UTC, shares in Neogenomics are trading at $13.53. This share price information is delayed by 15 minutes.
Shares in Neogenomics last closed at $13.53 and the price had moved by -14.8% over the past 365 days. In terms of relative price strength the Neogenomics share price has underperformed the S&P500 Index by -29.1% over the past year.
The overall consensus recommendation for Neogenomics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Neogenomics does not currently pay a dividend.
Neogenomics does not currently pay a dividend.
Neogenomics does not currently pay a dividend.
To buy shares in Neogenomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $13.53, shares in Neogenomics had a market capitalisation of $1.73bn.
Here are the trading details for Neogenomics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NEO
Based on an overall assessment of its quality, value and momentum Neogenomics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Neogenomics is $21.55. That is 59.28% above the last closing price of $13.53.
Analysts covering Neogenomics currently have a consensus Earnings Per Share (EPS) forecast of -$0.01 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neogenomics. Over the past six months, its share price has underperformed the S&P500 Index by -17.36%.
As of the last closing price of $13.53, shares in Neogenomics were trading -12.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Neogenomics PE ratio based on its reported earnings over the past 12 months is 368.62. The shares last closed at $13.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Neogenomics' management team is headed by:
- Lynn Tetrault - NEC
- Mark Mallon - CEO
- William Bonello - CFO
- George Cardoza - CEX
- Clive Morris - CEX
- Gina Wallar - CEX
- Cynthia Dieter - CAO
- Marcus Silva - CMO
- Stephanie Bywater - CCO
- Kathryn McKenzie - CRO
- Denise Pedulla - GCN
- Douglas Brown - OTH
- Jennifer Balliet - OTH
- David Daly - DRC
- Bruce Crowther - IND
- Alison Hannah - IND
- Stephen Kanovsky - IND
- Michael Kelly - IND
- Rachel Stahler - IND